Michael conducts due diligence on biotechnology companies at RA Capital. Toms primary responsibility is to support all aspects of trade and treasury operations. Scott brings to RAVen 20 years of experience working with clients and portfolio companies to complete transactions including multiple IPOs and acquisitions of portfolio companies. Raj is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. Andrews primary responsibility is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Prior to that, he held roles as Executive Vice President, Global Head Specialty Medicine and Vice President, Ophthalmology/Global Launch Team Head, EYLEA. She also gained administrative and client services experience in roles she held at Life Time Athletic, EF Education First, and at Beth Israel Deaconess Hospital ICU. Prior to Schrdinger, Cony was President Chief Business Officer at Proteros responsible for all commercial activities. He holds a BA from Cornell University and a PhD in Virology from Harvard University. Soumya completed his postdoc at Brigham and Womens Hospital and held an Assistant Professor of Neuroscience role at Harvard Medical School Neurology Department where he contributed to the Harvard Neurodiscovery Centers (HNDC) academic drug discovery initiative as a modeler and drug hunter. Cristina Montero is an Associate Director within the TechAtlas division of RA Capital Management. Joe brings to RA fifteen years of IT experience, beginning at the Apple Store and then transitioning to Boston Public Schools as an Apple Support Specialist. He has held multiple senior level clinical development positions including Chief Medical Officer at Asceneuron SA and Neurodegeneration Therapeutic Area Head at Novartis. FORBES estimates that Roivant is worth $3.5 billion, making its Millennial founder's 20% or so stake worth some $700 million. Join Peter Kolchinsky on his first episode of Future in Sight, a new podcast from FARE. Asthas primary responsibility is to identify needs for process improvement in the firm's data analytics and then both build and implement automated solutions. Previously, Laura covered hematologic malignancies, cell therapies, retinal diseases, and orphan neurodevelopmental disorders. Special Projects Operations Manager/Chief of Staff. In this role, he will work to evaluate and incubate early-stage therapeutic programs. Brendan holds a MS in Accounting with a concentration in Taxation from Merrimack College and a BA in Economics from University of Massachusetts Amherst. Michael has also previously held the position of Vice President and General Manager at Thomson Medstat (now part of IBM Watson Health), as well as held management roles at Immusol, a San Diego-based biotechnology company, HealthAllies, an organization created to provide discretionary medical benefits to the cash-pay market, and Da Vita, a national provider of dialysis services. Anthonys primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. She has published over fifty papers in peer reviewed journals. Prior to Relay, she worked as an Executive Assistant at Bullhorn, Inc. Phi holds an Associate in Science Business Administration from Middlesex Community College. Matt comes to RA from Localytics where he served as a Senior Software Engineer for the past two years. David holds a PhD from Harvard University in Biophysics and a BS in Molecular Biology from Texas A&M University. Mike is President and Chief Executive Officer of Sionna. His primary responsibilities are to advise RA Capital on private investments, coordinate with portfolio companies regarding deal structures and terms, and counsel RA Ventures on new company formation. Laura works on new company creation and early-stage investments, and serves as a Board Director for Be Biopharma, Expansion Therapeutics, Hemab, and Aliada Therapeutics. As the Chief Scientific Officer at Mustang Bio, Sadik managed the foundational build-out of the companys preclinical and manufacturing activities. In his Venture role, Mario is focusing on early-stage investment and company creation. Vikram trained in clinical pathology at the Brigham and Womens Hospital where he was chief resident. Before transitioning to industry, Cosmas was a faculty member at Harvard Medical School/Massachusetts General Hospital (MGH), where he had an active gastroenterology clinical practice and ran a lab whose research centered on fundamental aspects of RNA and epigenetics. More recently, Scott founded MissionGBM, a global community and resource focused on advancing brain cancer therapeutics development and care delivery. Ramaswamy, who just turned 30, has bigger aspirations. Previously, was a Research Analyst in the Kauwe lab at Brigham Young University. Maxs primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Matthew holds a BS in Environmental Health Science from the University of Georgia and both a PhD in Biomedical Science and an MBA with a concentration in Finance from the University of Connecticut. Jeff holds a BA in Economics and Psychology from Georgetown. Laura has a BS in Chemistry from Yale University and a PhD in Chemical Biology from Harvard University. Cosmas brings to RAVen over a decade of leadership experiences at the interface of basic science, drug development and clinical care. Michaels primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Phi previously worked as an Executive Assistant at Relay Therapeutics. Kriti previously served as Co-Director and Regional Director, South Asia for MIT Hacking Medicine. James was an entrepreneur in residence at HealthCare Ventures, an advisor to Kurma Ventures, and is on the Scientific Advisory Board and Board of Directors of the Friedreichs Ataxia Research Alliance (FARA), a patient advocacy group. "Too old," said a man in his 70s. Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Prior to this, she served as Director, Talent Acquisition and Operations at Flagship Pioneering, a role in which she built talent systems to support the growth of 30+ pre-series B biotech startup companies. As Director of Global Marketing, she provided global leadership for the launch of Otezla for the treatment of patients with psoriasis and psoriatic arthritis. Danielle Feldman is the Director of Corporate Development at Aliada Therapeutics. Since 2002, he has been working in start-up pharma companies, including co-founding Thesan Pharmaceuticals and NeoKera, where he assumed responsibilities for all development activities, including regulatory affairs. Prior to this role, Tom conducted research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities as a Senior Research Assistant. Nate conducts due diligence on biotechnology companies at RA Capital and serves as a Board Director for The Covid Apollo Project and Nucleix. Prior to Bernstein, Joey held a Consultant role at FactSet. Christy has an MS in Immunology from National Taiwan University, a PhD in Immunology and Microbial Pathogenesis from Cornell University, and a mini-MBA in BioPharma Innovation from Rutgers Business School. Dans primary responsibility at RA Capital is to identify compelling opportunities to help facilitate new company creation or investments in emerging seed-stage companies. Jeff Breay is a Head Trader at RA Capital Management. Christina holds a PhD in Neuroscience from the Ichan School of Medicine at Mount Sinai and a BS in Biochemistry from Stockholm University. Ding Sun is a Senior Software Engineer at RA Capital Management. He co-founded and runs the Boston-based investment firm RA Capital Management; writes and teaches about biomedical entrepreneurship and its potential to transform global health; serves on the boards of several public and private drug development companies; and lives in Massachusetts with his historian/equestrian wife, strong-willed children, and reasonably well-trained dog. Prior to joining RA, Kyle was a Partner at Breakthrough Energy Ventures (BEV), where he led investments and served on company boards that span the utilities, energy storage, chemicals, agriculture, automotive, recycling, and consumer products sectors. Brians primary responsibility at RA Capital is to conduct due diligence on biotechnology companies. Harvey most recently served as Assistant Controller at Charles River Ventures. Drews primary responsibility is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Support. Priscilla Lee is an Associate within the TechAtlas division of RA Capital Management. He had to juggle the demands of raising a family while also trying to pay for his children's education. Michael holds a B.S. Prior to joining RA, Brigid was the Head of Venture Investments for BHP Ventures, the internal venture capital unit within the worlds largest mining company, where her investment mandate was to help the decarbonization of BHPs operations and to improve the sustainability of resource extraction. Previously he served as the Director of Pharmaceutical Sciences at the Clinton Health Access Initiative. Adam Rosenberg is an Advisor for RA Capital Management. The market worked. Kaleens primary responsibility is to oversee the initiation, planning, and execution of various projects within the TechAtlas Division. Joshs primary responsibility at RA Capital is to lead early-stage private investments in and oversee the creation of new companies developing drugs, medical devices, diagnostics, and research tools. Prior to Blueprint Medicines, he spent two years at Lonza Pharma & Biotech, most recently as Product Development Scientist. Erin Clutter is the Head of Graphics at RA Capital Management. Prior to joining RA, Emily was Chief Business Officer of Prevail Therapeutics from the companys inception in 2017 until its acquisition by Eli Lilly in 2021. Copyright 2001-2023 RA Capital Management, L.P. Laura is an Executive Assistant at RA Capital Management. Habib received his BBA in Marketing & Finance and his MBA in International Business from University of New Brunswick. Walter's primary responsibility at RA Capital is to create competitive landscapes of biotechnology and planetary health. 1 reply 0 retweets 13 likes Prior to joining RA Capital, Mario was Associate Vice President for Advanced Research at Sanofi Pasteur and Head of the team executing a strategy for integrating influenza vaccine development with machine learning and antigen design. Prior to Proteros, Cony was Senior Vice President, Business Development, North America for Evotec and was responsible for managing all commercial activities of Evotec in North America. Lorena has dual degrees from Beijing Foreign Studies University: a Bachelor of Business Administration in Accounting and a Bachelor of Arts in English Literature. His doctoral research focused on breast cancer metastasis. Cristinas primary responsibility is to identifying compelling opportunities to help facilitate new company creation and early stage investing. He holds a BS in Computer Engineering and a Minor in Mathematics from Northeastern University. Roivant, he . Kathryn's primary responsibilities at RA Capital are to coordinate calendars, events, and company meetings for the TechAtlas division. Samuel Chowdhury is a Software Engineerat RA Capital Management. Prior to Point32Health, Michael served as CMO of Harvard Pilgrim Health Care, the Corporate Medical Director at Humana and also served as Vice President of Network and Consumer Solutions for UnitedHealth Groups subsidiary Ingenix (now part of Optum). Dan holds a BS with Honors in Biology from Yale University and a PhD in Cancer Biology from the Gerstner Sloan Kettering School of Biomedical Sciences. Josh holds a BA in Chemistry from Williams College, an MD from the University of Pennsylvania School of Medicine, and an MBA from the Wharton School of Business. She received a BA from Princeton University and an MBA from Harvard Business School. Habib has earned his Director Professionalism Certificate from the National Association of Corporate Directors. Prior to MRL Ventures, Josh was a Venture Partner with Atlas Venture and a Partner at Prism Venture Partners, focusing on company formation and seed and Series A investing. Prior to MassTech, Natalie held varying Administrative roles at Northeastern University, Framingham Public Schools, and Bright Horizons Family Solutions. Ed has 30 years of experience in preclinical and clinical drug development, and in regulatory affairs for pharmaceutical and biotechnology companies. Pieter Boelhouwer is a Partner and Managing Director of Strategy and Operations at RA Capital Management. He is a member of the Advisory Boards of the Applied Biotechnology Laboratory at the Francis Crick Institute, the Center for Surgery,Innovation & Bioengineering at the Massachusetts General Hospital/Harvard MedicalSchool; the Chemical& Biomolecular Engineering Department of the University of Illinois and the Biomedical Engineering Departmentof Rutgers University. Prior to joining RAVen, Joel was co-founder, President and Chief Scientific Officer at Jnana Therapeutics, a platform company focused on unlocking hard-to-drug targets. TJ is a Senior Fund Accountant at RA Capital Management. James holds a BS in Journalism from Boston University and a JD from Boston College Law School. He earned an MS in chemical engineering and his MBA and PhD in engineering systems from MIT. Craig is admitted to practice law in the Commonwealth of Massachusetts. Dings primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Kathryn holds a BA in Geography and Peace and Conflict Studies from Colgate University, a MSc in International Development: Environment and Development from the University of Manchester (UK), and a MA and Ph.D. in Geography from Clark University (2016). Generali's No.3 investor Caltagirone withholds backing for 2022 accounts -sources, Musk says Tesla likely to launch full self-drive technology 'this year', Exclusive: JPMorgan employees gripe about Dimon's return-to-office edict, SpaceX rocket explosion illustrates Elon Musk's 'successful failure' formula, Cucinelli posts 33% rise in Q1 sales, confirms 2023 revenue growth forecast, Exclusive-Peter Thiel, Republican megadonor, won't fund candidates in 2024 - sources, Virginia Governor Youngkin 'humbled' by talk of possible presidential run, European Midday Briefing: Mood Brighter After -2-, Tim Cook unveils new Apple store in India, Morgan Stanley's dealmaking CEO Gorman signals more transactions to come, RA Capital Management LP (Private Equity). Prithviraj works on both public and private investments with a focus on Healthcare, Technology, and Services. He completed the Executive Program at Stanford University, Graduate School of Business, as well as the Executive to Leader Institute at Korn/Ferry International. Adison is an Executive Assistant RA Capital Management. Mark began his professional career as a life sciences attorney with the law firm of Hale and Dorr (now WilmerHale). In this episode Peter speaks with Dr. Wayne Shreffler, Director of the Food Allergy Center at Massachusetts General Hospital & Division Chief of Pediatric Allergy and Immunology at MassGeneral Hospital for Children. Mario is a Venture Partner and Head of Vaccines at RA Capital. This is a re-publication of an op-ed that first appeared in the Wall Street Journal on September 30, 2018 and is now included in The Biotech Social Contract series of . Emily Greenis a Visual Identity Designer at RA Capital Management. He was named an MIT Technology Review 100 innovators under 35 for his MIT Media Lab social enterprise, Dimagi, that has impacted millions with its mobile data collection platform. Jessica holds a BA in Linguistics from Brigham Young University and a PhD in auditory neuroscience from the Division of Medical Sciences at Harvard University. Erins primary responsibilities at RA Capital are to manage the design and creation of all internal and external documents and resources for the company, including competitive landscapes of drugs and medical devices for disease indications and capabilities, set brand standards, and oversee internal and external marketing efforts. Emilies primary responsibility at RA Capital is to manage current and potential investor relationships. Kevin Grosselin is RA Ventures Associate at RA Ventures (RAVen). Matts primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. He was also a Board Member of the Fannie & John Hertz Foundation and served as a judge for the Lemelson-MIT StudentPrize for Inventorship. Prior to moving to BMS, he spent five years at Hoffmann La-Roche as a research scientist. Parents need to know that Peter Pan & Wendy takes on some of the weightier themes of J.M. Alex comes to RA from Mirai Advisory, where he specialized in financial risk and data science and developed machine learning algorithms to support banks managing regulatory and operational challenges. He also served as member of the Product Advisory Board at Concert Pharmaceuticals and as an Advisor to Nimbus Therapeutics. Prior to founding The Branta Group LLC in 2003, he was a co-founder and Chief Business Officer of Orchid GeneShield, a subsidiary of Orchid BioSciences (Nasdaq: ORCH), which was formed after he acquired a healthcare informatics company and merged it with Orchids pharmacogenetics business to create innovative personalized consumer healthcare products in partnership with leading healthcare companies. This website is for informational purposes only and does not constitute an offer to provide investment advisory or other services by RA Capital Management, L.P. (RA Capital). Jesse has more than a decade of discovery research and management experience, from early discovery through preclinical development. Prior to RA, TJ was at KPMG where he was a Senior Audit Associate. James was a post-doctoral fellow at Massachusetts Institute of Technology and University of California, Berkeley. Peter Kolchinsky, Ph.D. Dan Marks is a Principal on the Venture Team at RA Capital Management. Milind has more than 25 years of leadership and operational experience through all stages of drug discovery and development. During his time at Flagship, Tom also served as Co-Founder, Head of Translational Biology at a stealth ProtoCo. "He'll be 86 by the time it's over," said a woman in her 50s, noting the age Biden would be if he wins re-election and serves out a second term. Mariagrace Houllahan is an Executive Assistant at RA Capital Management. Meredith holds a BS in Biology: Pre-Med from the University of North Carolina at Charlotte. Amber is Special Projects Operations Manager/Chief of Staff at RA Capital Management. Mark Boshar is a Venture Partner at RA Ventures (RAVen), focusing on new company creation. Sophie is Chief Medical Officer at Enara Bio, a company focused on novel targets for cancer immune therapy drug discovery. Prior to RA, Ryan was at KPMG where he was a Senior Associate. Peter Kolchinsky, Ph.D. is a biotechnology investor and a scientist. Asthas previous experience includes Research Assistant roles at Clark University and Corbus Pharma. Anthony has a BS in Molecular and Cellular Biology from University of Arizona and a PhD in Genetics and Molecular Biology from University of North Carolina at Chapel Hill. Kate Moreau is an Associate Director within the TechAtlas division of RA Capital Management. She earned an MBA with focus in entrepreneurship & strategic management from AB Freeman School of Business at Tulane University and her MD from Tulane School of Medicine. Prior to joining RA Capital, Emilie was a Vice President of Investor Relations at THL Credit. Sarah teaches a course at Harvard Law School on venture capital fund formation. Brendan has more than 18 years of experience as a tax professional. Abhishek has a BS in Bioproducts and Biosystems Engineering and a BS in Chemistry from University of Minnesota, Twin Cities. Jaimie Kirkpatrick is a Research Assistant at RA Capital Management. Prior to Q32 Bio, Maryann worked as the Operations Manager for Surface Oncology and several other biotech start-up companies from discovery research through end of Phase 2 Clinical trials. Prior to Avilar, Mr. Grau was CEO at Sojournix, President at Heptares Therapeutics (acquired 2015), CEO at Cortria (acquired 2010), and COO at CombinatoRx (IPO 2005). As a founder and member of Constellations executive team Patrick materially contributed to several successful financing rounds and deals, including a crossover round, an IPO and the ultimate acqusition of the company. His graduate research focused on identifying novel targets for disrupting the cell cycle in cancer cells.
Where Does Marshall Faulk Live Now,
List Of Nxt Tag Team Champions,
Village Market Roslindale Weekly Flyer,
Articles P
